Showing results (1-10 of 34) with videos related to

Sort By:
Pageof 4
Current Pharmaceutical Biotechnology|April 28, 2010
Causes and effects of cellular oxidative stress as a result of MDMA abuseAnna Ida Fiaschi, Daniela Cerretani
Cancer Investigation|May 8, 2015
Targeted Therapies for Prostate CancerRoberto Petrioli, Edoardo Francini, Anna Ida Fiaschi, et al.
Cancer Treatment Reviews|July 16, 2008
The role of doxorubicin and epirubicin in the treatment of patients with metastatic hormone-refractory prostate cancerRoberto Petrioli, Anna Ida Fiaschi, Edoardo Francini, et al.
Medicine|December 16, 2014
Effects of abiraterone acetate on chronic kidney disease in 2 patients with metastatic castration-resistant prostate cancerEdoardo Francini, Roberto Petrioli, Anna Ida Fiaschi, et al.
Cancer Chemotherapy and Pharmacology|June 18, 2015
Role of chemotherapy in the treatment of metastatic castration-resistant prostate cancer patients who have progressed after abiraterone acetateRoberto Petrioli, Edoardo Francini, Letizia Laera, et al.
Reproductive Biology|October 23, 2017
Nitric oxide, malondialdheyde and non-enzymatic antioxidants assessed in viable spermatozoa from selected infertile menElena Moretti, Giulia Collodel, Anna Ida Fiaschi, et al.
Oxidative Medicine and Cellular Longevity|November 28, 2019
Resistin in Human Seminal Plasma: Relationship with Lipid Peroxidation, CAT Activity, GSH/GSSG Ratio, and Semen ParametersElena Moretti, Lucia Micheli, Daria Noto, et al.
Clinical Colorectal Cancer|March 18, 2018
Efficacy and Safety of Regorafenib With 2/1 Schedule for Patients ≥ 75 Years With Metastatic Colorectal Cancer (mCRC) After Failure of 2 Lines of ChemotherapyRoberto Petrioli, Martina Chirra, Luciana Messuti, et al.
Cancer Chemotherapy and Pharmacology|January 26, 2015
Gemcitabine, oxaliplatin, and capecitabine (GEMOXEL) compared with gemcitabine alone in metastatic pancreatic cancer: a randomized phase II studyRoberto Petrioli, Giandomenico Roviello, Anna Ida Fiaschi, et al.
Anti-Cancer Drugs|June 9, 2015
Carboplatin, methotrexate, vinblastine, and epirubicin (M-VECa) as salvage treatment in patients with advanced bladder cancer: a phase II studyRoberto Petrioli, Giandomenico Roviello, Anna Ida Fiaschi, et al.
Pageof 4